Enzo Biochem Inc

NYSE:ENZUnited States

Oct 29, 2024

Show headlines and story abstract

• Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend, from 7:59PM ET on Tuesday Oct 29, 2024 by Dow Jones

  7:59PM ET on Tuesday Oct 29, 2024 by Dow Jones
  Companies Mentioned: ENZ
  and diluted common share ($0.51) $0.41 ========= ========= Weighted average common shares outstanding - basic and diluted 50,902 49,160 ========= ========= 7/31/2024 7/31/2023 Selected balance sheet data: (unaudited) (unaudited) ----------------------------------- -------------- -------------- Cash and cash equivalents (includes restricted cash of $1,000 at 7/31/23) $ 52,371 $ 83,373 Working capital 45,237 58,467 Stockholders' equity 56,112 78,462 Total assets 85,764 121,880 The following table presents a reconciliation of reported net loss and basic and diluted net loss per share to Adjusted net loss and Adjusted basic and diluted net loss per share for the twelve months ended July 31, 2024. ENZO BIOCHEM, INC. Non-GAAP Reconciliation Table (Unaudited, in thousands, except per share data) Twelve months ended July 31, ----------------------- 2024 -------------- Reported GAAP loss $ (26,078) Adjusted for: Discrete legal matters 2,377 Fair value adjustment 1,095 Discrete separation expenses 1,742 Net loss from discontinued operations 16,261 Adjusted net loss $ (4,603) === ============== Weighted Shares Outstanding: Basic and diluted 50,902 Basic and diluted earnings per share: Basic and diluted net loss per share GAAP ($0.51) Basic and diluted net loss per share non-GAAP ($0.09) The following table presents a reconciliation of reported GAAP net loss for the twelve months ended July 31, 2024 to EBITDA and Adjusted EBITDA: ENZO BIOCHEM, INC. EBITDA & Adjusted EBITDA Reconciliation Table (Unaudited, in thousands) Twelve months ended July 31, ------------------------- 2024 -------------- GAAP net loss $ (26,078) Plus (minus): Depreciation and amortization 1,272 Interest (income) expense, net (3,341) Income tax benefit - discontinued operations (390) EBITDA (28,537) Adjusted for: Discrete legal matters 2,377 Fair value adjustment 1,095 Discrete separation expenses 1,742 Net loss from discontinued operations before income tax benefit 16,651 Foreign exchange loss 192 Adjusted EBITDA $ (6,480) === ==============
  

• Press Release: Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend, from 7:59PM ET on Tuesday Oct 29, 2024 by Dow Jones

  7:59PM ET on Tuesday Oct 29, 2024 by Dow Jones
  Companies Mentioned: ENZ